Genetically-Engineered Biological Agents for Scleroderma: Literature Review and Case Report
Objective of the Review: To analyze recent publications about genetically-engineered biological agents that are used to treat different forms of scleroderma (SD) in adults and children. Key Points: This review describes trials that provided information about SD pathogenesis, which helped justify the use of genetically-engineered biological agents in patients with this disease. These agents were shown to reduce skin fibrosis, joint lesions, and, in some cases, interstitial pneumonitis. The authors describe their own successful experience of using tocilizumab in a child with scleroderma en coup de sabre, accompanied by epilepsy and uveitis. Conclusion: It has been demonstrated that genetically-engineered biological agents are effective in treating some severe forms of scleroderma. This makes them promising options for this patient population.